# SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

> **NCT02270463** · PHASE1,PHASE2 · TERMINATED · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Tagraxofusp-erzs

## Key facts

- **NCT ID:** NCT02270463
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02270463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02270463, "SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02270463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*